TLR2 Agonist Compounds for Preemptive Respiratory Infection Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for respiratory infections and exacerbations associated with viral or bacterial infections, such as asthma and COPD, are inadequate and lack effective prevention and treatment options, particularly during seasonal influenza outbreaks and pandemics.
Innovation Solution
Development of Toll-Like Receptor 2 (TLR2) agonist compounds and compositions, specifically formulated compounds of type (VI) and (VII), which stimulate the innate immune response to treat and prevent respiratory diseases and conditions associated with infectious agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are used for seasonal influenza strains, then protection against known strains is provided, but protection is inadequate due to lag phase between inoculation and antibody formation, and vaccines need frequent re-formulation
Solution Approach 1:
The patent applies preliminary action by using TLR2 agonists to activate the innate immune system before viral infection occurs. This pre-activation of immune cells (macrophages, dendritic cells, NK cells) through TLR2 stimulation creates a ready-state immune response that does not require the lag phase associated with adaptive antibody formation. The innate immune system is primed to respond immediately upon pathogen encounter.
2Ease of operation
If conventional treatments (increased bronchodilators and corticosteroids) are used for exacerbations, then treatment options are available, but these treatments fail to prevent exacerbations from occurring in the first place
Solution Approach 1:
The patent applies preliminary action by using TLR2 agonists prophylactically to prevent exacerbations before they occur. Rather than treating exacerbations after they manifest with bronchodilators and corticosteroids, the TLR2 agonist compounds prime the innate immune system in advance, creating protective immunity that prevents the inflammatory cascade leading to exacerbations.
Solution Approach 2:
The patent uses TLR2 agonists as intermediary substances that bridge the gap between pathogen detection and immune activation. These compounds bind to TLR2 receptors on immune cells, serving as a mediator that triggers innate immune responses without requiring direct pathogen exposure or the complex adaptive immune response pathway.
3Reliability
If TLR2 agonist compounds are developed to stimulate innate immune response, then prevention and treatment of respiratory infections is improved, but compound structure and formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of TLR2 agonist compounds to optimize their properties. This includes varying the lipopeptide backbone structure, changing fatty acid chain lengths and compositions, modifying amino acid sequences, and adjusting PEGylation parameters to achieve compounds with improved stability, potency, and pharmacokinetic profiles while managing structural complexity.
Solution Approach 2:
The patent uses composite materials by combining different molecular components into TLR2 agonist compounds. These include lipopeptide backbones with specific amino acid sequences, fatty acid chains of varying lengths, PEG chains for solubility and stability, and various functional groups. The composite nature of these compounds allows optimization of multiple properties simultaneously.
Data Source
Figure 1A~2C
Figure 3~4
Figure 5
AI summary
The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.